| BUY | 56.980 | Ian Nakamoto | One of the major concerns that pharmacy companies have is patent expiration and generics coming in. Doesn't think they have any major products coming off patents until 2010. | 2006-11-07 | |
| BUY | 56.010 | Norman Levine | Hasn't gone anywhere because it hasn't any blockbuster drugs. Has a good pipeline. Demographically, diabetes is set to explode. | 2006-10-31 | |
| HOLD | 56.970 | Laura Wallace | Eli Lilly is a good company. It looks fine. It has come down with the other large cap drug stocks in the States. Need to be patient. It offers decent value here. | 2006-03-15 | |
| DON'T BUY | 53.500 | David Burrows | This is a part of the market that's lagging. There has been such a slowdown in the growth rates. | 2005-08-25 | |
| DON'T BUY | 56.370 | David Burrows | Prefers others such as Abbott Labs (ABT-N). | 2005-07-13 | |
| WEAK BUY | 59.750 | David Burrows | Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics. | 2005-05-03 | |
| BUY | 52.700 | George Loughery | A little bit of risk in a 3/6 month view as to whether they can retain their patent on Sprizecta (?), but the longer term they have the best drug pipeline and growth in the sector. OK for a long term hold. | 2005-03-15 | |
| TOP PICK | 61.570 | Samuel D. Isaly | Lots of new products. Rapid profit growth. | 2004-08-13 | |
| TOP PICK | 66.300 | Alan Blake | Powerful balance sheet. | 2004-07-16 | |
| TOP PICK | 72.450 | Richard Bernstien | | 2004-04-16 | |
| DON'T BUY | 78.740 | Joe Connolly | Has a very good pipeline. Getting more competition from generic drugs. Too focused on Prozac. | 2002-04-02 | |
| BUY | 81.540 | David Burrows | Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot | 2001-12-10 | |
| DON'T BUY | 77.270 | Neil Murdock | Some of their drugs are coming off patent and others not doing as well. Prefers Pfizer or J & J. | 2001-10-30 | |
| HOLD | 77.200 | Brad Willock | Good pipeline for new drugs but prefers Pfizer. | 2001-09-10 | |
| DON'T BUY | 88.100 | Ross Healey | Prozac about to go generic. | 2001-06-05 | |
Experts that have talked about Eli Lilly & Co.
Rss Feed